[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-neoplasms":716},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,48,83,122,147,185,217,244,273,300,326,346,379,402,430,451,474,496,523,544,567,590,614,666,685],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100205406",false,"NCT01950572","Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma","Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers","* INCLUSION CRITERIA:\n* All participants \\>= 2 years of age with malignant mesothelioma.\n* All participants \\>=18 years of age with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin.\n* Confirmed pathological diagnosis is required\n* Ability and willingness of participant to provide informed consent to participation.\n\nEXCLUSION CRITERIA:\n\n* Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.\n* Pregnant women.\n* Active concomitant medical or psychological illnesses that may increase the risk to the participant or in adult participants, inability to obtain informed consent, at the discretion of the principal investigator.","ALL","2 Years","100 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis.\n* Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States.\n* The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis.\n* Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease.\n* In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma.\n\nObjectives:\n\n-To allow sample acquisition for use in the study of mesothelioma.\n\nEligibility:\n\n* All participants age greater than or equal to 2 years with malignant mesothelioma OR\n* All participants greater than or equal to 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin\n* Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18\n\nDesign:\n\n* Up to 1000 subjects will be enrolled.\n* Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma.\n* Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking.\n* Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.",[25,26,27,28,29,30],"Thymoma","Stomach Neoplasms","Pancreatic Neoplasms","Mesothelioma","Biliary Tract Neoplasms","Mesothelin Expressing Neoplasms",[32,33,34,35,36],"Samples","Biobank","Lung Neoplasms","Ovarian Neoplasms","Natural History","RECRUITING","2026-06-24",{"date":40,"type":41},"2026-06-25","ACTUAL",{"date":43,"type":41},"2013-09-09",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",1,{"id":49,"slug":4,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100637784","NCT07605819","Pancreatic Cancer Screening Using the Enzeavour Assay in Japan","Pancreatic Cancer Screening Using Single-Molecule Enzyme Activity-Based Liquid Biopsy, Enzeavour: A Single-Arm Interventional Feasibility Study Protocol in Japan","ENZEAVOUR FS","Inclusion Criteria:\n\n* Asymptomatic adults attending participating facilities for routine health checkups, organized cancer screening, or both\n* Able to understand the study procedures and provide written informed consent before enrollment\n\nExclusion Criteria:\n\n* Documented clinical history of pancreatic cancer\n* Considered unable or unwilling to undergo any required diagnostic imaging modality (MRCP, EUS, or contrast-enhanced CT) after a positive index test result\n* Any medical, psychological, or social condition that, in the opinion of the principal investigator at each participating site, makes participation inappropriate or compromises study integrity",true,"20 Years",{"count":58,"type":21},10000,"INTERVENTIONAL",[61],"NA","This nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer screening in Japan. Approximately 10,000 asymptomatic adults will be enrolled. Participants with an Enzeavour Score above 0.369 will undergo diagnostic work-up as clinically indicated. The primary outcome is pancreatic cancer detection rate within 12 months after the index blood draw, and the secondary outcome is positive predictive value.",[64,27],"Pancreatic Cancer",[66,67,68,69,70,71],"pancreatic cancer screening","liquid biopsy","blood-based biomarker","early detection","Enzeavour","single-molecule enzyme activity","2026-06-23",{"date":74,"type":41},"2026-06-26",{"date":76,"type":41},"2026-02-04",{"date":78,"type":21},"2028-12-31",{"name":80,"class":81},"Cosomil, Inc.","INDUSTRY",48,{"id":84,"slug":4,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100644615","NCT07670871","Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology","EXPAND","Inclusion Criteria:\n\n* Adults aged 20 to 78 years.\n* Ability and willingness to provide written informed consent.\n* Eligibility for one of the study cohorts:\n* Individuals undergoing pancreatectomy for non-endocrine pancreatic disease.\n* Individuals with pancreatic ductal adenocarcinoma undergoing pancreatectomy.\n* Individuals with chronic pancreatitis or a previous episode of acute pancreatitis.\n* Individuals at increased risk of type 2 diabetes mellitus, including impaired fasting glucose and\u002For impaired glucose tolerance.\n* Individuals with newly diagnosed type 2 diabetes mellitus.\n* Ability to undergo study-related metabolic assessments and sample collection procedures.\n\nExclusion Criteria:\n\n* Age \\\u003C20 years or \\>78 years.\n* Inability or unwillingness to provide informed consent.\n* Pregnancy or breastfeeding.\n* Diagnosis of type 1 diabetes mellitus.\n* Participation in another interventional clinical trial involving an investigational medicinal product within 30 days before enrollment.\n* Clinical conditions that preclude completion of the planned metabolic assessments.\n* Inability to comply with study procedures.","78 Years",{"count":91,"type":21},440,"The EXPAND study is a prospective observational study designed to investigate the biological mechanisms underlying the heterogeneity of type 2 diabetes and related metabolic disorders.\n\nThe study will enroll adults with and without pancreatic disease, including patients undergoing pancreatic surgery, individuals with chronic pancreatitis, subjects at high risk of type 2 diabetes, and patients with newly diagnosed type 2 diabetes. Clinical, metabolic, imaging, genetic, microbiome, and molecular data will be integrated to identify distinct metabolic endotypes and to investigate the interactions between the exocrine pancreas, endocrine pancreas, and adipose tissue. The ultimate goal is to improve the understanding of diabetes pathophysiology and support the development of precision medicine approaches.",[94,95,96,27],"Type 2 Diabetes Mellitus (T2DM)","Chronic Pancreatitis","Prediabetes",[98,99,100,101,102,103,104,105,106,107,108,109,110,111],"Metabolic Endotypes","Beta Cell Function","Insulin Secretion","Insulin Sensitivity","Exocrine Pancreas","Endocrine Pancreas","Pancreatic Crosstalk","Precision Medicine","Glucose Metabolism","Oral Glucose Tolerance Test","Genetic Risk Score","Fat Adipose Tissue","Hyperglycemic Clamp","Microbiome","NOT_YET_RECRUITING","2026-06-22",{"date":74,"type":41},{"date":116,"type":21},"2026-09",{"date":118,"type":21},"2031-09",{"name":120,"class":121},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",{"id":123,"slug":4,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":47},"100390947","NCT04370574","Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology","Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology (PanEXPEL2)","PanEXPEL2","Inclusion Criteria:\n\n* Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy\n\nExclusion Criteria:\n\n* Vulberable person according to L1121-6 of Public health reglementation in France\n* Pregnant women","18 Years",{"count":131,"type":21},200,"Pancreatic ductal adenocarcinoma (PDAC) remains among cancers with a very poor prognosis (1-year survival \\\u003C20%). Endoscopic ultrasound with fine needle aspiration (EUS\u002FFNA) is the common examination for all patients with suspicious pancreatic mass. A method was recently developed : it preserves the sanitary sample, named EXPEL, which allows standard pathology examination and OMICS analyzes from the \"rinse\" liquid. After EUS\u002FFNA in clinical practice, the content of the needle is rinsed in CytoLyt® preservative solution. After cytofiltration, this liquid is systematically discarded.\n\nBased on the EXPEL concept, we hypothesise that this all-patients inclusive approach (\"Modified EXPEL\" procedure) combined with the methodology to access proteomic and metabolomics information in these original samples will allow us to identify a series of clinically useful marker signatures that will ultimately be measurable, non-invasively, in the patient blood.",[27],[135,136,137,138],"Biopsy","Fine-Needle","diagnostic imaging","Endosonography","2026-06-17",{"date":113,"type":41},{"date":142,"type":41},"2021-01-14",{"date":144,"type":21},"2027-07",{"name":146,"class":121},"University Hospital, Montpellier",{"id":148,"slug":4,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":59,"phases":156,"briefSummary":157,"conditions":158,"keywords":166,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":184},"100641147","NCT07658313","Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery","From Prehabilitation to Rehabilitation: A Feasibility Trial for Digitally Supported Prehabilitation in Major Visceral Oncologic Surgery","P2R-OncoVis","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Clinical diagnosis requiring major surgery of the pancreas, liver, bile ducts, stomach, or esophagus with curative intent\n* Confirmed indication for surgery by the multidisciplinary tumor board\n* Medical stability and physician clearance to participate in a prehabilitation exercise program\n* Willingness and ability to attend center-based prehabilitation exercise sessions three times per week, or once per week with additional tele-prehabilitation if travel time exceeds 40 minutes one way\n* Willingness and ability to perform home-based physical activities\n* Sufficient German language proficiency and digital literacy\n* Access to a smartphone or tablet device with internet connection\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Physical disability or mental impairment preventing safe participation in the study\n* Health care medical power of attorney not permitting independent consent\n* Non-elective, emergency, or revision surgery\n* Acute medical condition contraindicating participation in a structured prehabilitation program",{"count":155,"type":21},30,[61],"Major visceral oncologic surgery is associated with high postoperative morbidity, prolonged hospitalization, delayed recovery, and reduced quality of life. Patients undergoing surgery of the pancreas, liver, bile ducts, stomach, or esophagus frequently present with reduced physical fitness, malnutrition, sarcopenia, and psychological distress, all of which may negatively affect surgical outcomes and rehabilitation. Although prehabilitation has shown potential to improve functional capacity before surgery, structured prehabilitation pathways are currently not routinely implemented in Austria, and the feasibility of digitally supported perioperative care pathways remains insufficiently evaluated.\n\nThe aim of the Prehab2Rehab-OncoVis study is to evaluate the feasibility, acceptability, and safety of a multimodal, digitally supported prehabilitation intervention for patients undergoing major visceral oncologic surgery with curative intent. The study will additionally explore potential effects on clinical recovery, functional capacity, rehabilitation outcomes, and patient-reported outcomes across the perioperative pathway.\n\nPrehab2Rehab-OncoVis is designed as a prospective, single-arm feasibility cohort study conducted at the University Hospital Salzburg and the University Institute of Sports Medicine, Prevention and Rehabilitation, coordinated by the Paracelsus Medical University in cooperation with the Ludwig Boltzmann Institute for Rehabilitation Research and the Ludwig Boltzmann Institute for Digital Health and Prevention within the Prehab2Rehab consortium. Approximately 30 adult patients, with the possibility to include up to 50 participants if feasible, will be consecutively recruited.\n\nThe intervention consists of a four-week multimodal prehabilitation program combining supervised exercise training, promotion of physical activity, nutritional counseling, psycho-oncological distress screening, and health literacy support. Digital tools will support the intervention throughout the perioperative pathway, including the HERO application (Das Herz Reha-Informationstool) for patient education and health literacy, aktivplan as a digital exercise planner and training diary, and the CAATS telecommunication platform for remote supervision and tele-prehabilitation sessions where appropriate.\n\nThe exercise intervention includes supervised center-based sessions and, for participants with longer travel distances, a hybrid model combining center-based and tele-prehabilitation sessions. Nutritional counseling will follow current European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines and includes screening for malnutrition risk. Psycho-oncological distress screening will follow recommendations of the German Cancer Society and includes referral to supportive care when clinically indicated.\n\nParticipants will be assessed throughout the perioperative pathway, including at the beginning and end of prehabilitation (Prehabilitation Assessment 1 \\[PRE1\\] and Prehabilitation Assessment 2 \\[PRE2\\]), during hospitalization and rehabilitation, and at a three-month follow-up after surgery. Primary outcomes focus on feasibility, including recruitment and retention rates, adherence, fidelity, safety, data management feasibility, and acceptability and usability of the digital technologies. Secondary outcomes include clinical recovery indicators, postoperative complications, length of hospital and intensive care stay, functional independence, psychological well-being, quality of life, body composition, cardiorespiratory fitness, functional exercise capacity, and muscle strength.\n\nTo contextualize outcomes, two historical comparator cohorts will be used: a local hospital cohort of patients who previously underwent similar surgery without prehabilitation, and a national rehabilitation cohort derived from routine rehabilitation datasets matched for diagnosis, sex, and age.\n\nThe study is intended to generate feasibility data and preliminary estimates that may support the development of future adequately powered randomized controlled trials evaluating digitally supported prehabilitation and rehabilitation pathways in visceral oncologic surgery.",[159,27,160,161,162,64,163,164,165],"Gastrointestinal Neoplasms","Liver Neoplasm","Oesophageal Cancer","Gastrointestinal Cancer","Liver Cancer","Prehabilitation","Cancer Rehabilitation",[164,167,168,169,170,171,172,173,174,175],"Visceral Surgery","Oncology","Rehabilitation","Digital Health","Exercise Therapy","Teleprehabilitation","Cancer Surgery","Preoperative Care","Functional Recovery","2026-06-16",{"date":178,"type":41},"2026-06-18",{"date":180,"type":21},"2026-06",{"date":144,"type":21},{"name":183,"class":121},"Ludwig Boltzmann Institute for Digital Health and Prevention",2,{"id":186,"slug":4,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":59,"phases":194,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":47},"100584158","NCT06885697","Anti-Mesothelin TNaive\u002FSCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma","Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive\u002FSCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria. For this protocol, treatment initiation is defined as the first day of lymphodepleting chemotherapy.\n\n* Participant must have unresectable, locally advanced, or metastatic, or recurrent mesothelioma and other mesothelin expressing solid tumors. For participants with mesothelioma only those with epithelioid or biphasic histology (with \\>80% epithelioid component) will be eligible. The diagnosis will be confirmed by the Laboratory of Pathology, CCR, NCI.\n* Participant must have progressed on at least one FDA-approved systemic therapy considered standard of care for their tumor type. There is no limit on the number of prior treatment regimens. Note: Given the aggressive nature of pancreatic cancer, otherwise eligible individuals with this cancer type can undergo leukapheresis before or while they are getting their frontline treatment as long as they meet all other inclusion criteria. However, TNhYP218 CAR T cells will only be administered after progression on first line standard of care therapy.\n* Participant must have at least 1 measurable lesion by RECIST version 1.1.\n* Tumor must have MSLN positivity of 2+ to 3+ in \\>= 50% cancer cells by immunohistochemistry on freshly collected biopsy or archival tissue.\n* Age \\>= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate organ and marrow function as defined below:\n\nSystem: Laboratory Value\n\nHematological\n\n* Hemoglobi: \\>=9 g\u002FdL(a)\n* absolute neutrophil count: \\>=1,500\u002FmcL\n* platelets: \\>=100,000\u002FmcL\n\nHepatic\n\n* total bilirubin: \\\u003C=2.5 X institutional ULN OR direct bilirubin ULN for participants with total bilirubin levels \\>1.5 X ULN\n* AST and ALT \\\u003C= 2.5 X institutional ULN (\\\u003C= 5 X ULN for participants with liver metastases)\n\nRenal\n\n* Creatinine OR: \\\u003C=1.5 X ULN OR\n* Calculated(b) creatinine clearance (GFR can also be used in place of creatinine or CrCl) \\>= 50 mL\u002Fmin for participant with creatinine levels \\> 1.5 X institutional ULN\n\nCoagulation\n\n* International normalized ratio (INR) OR prothrombin time (PT): \\\u003C=1.5 X ULN unless participant is receiving anticoagulant therapy if PT or aPTT is within therapeutic range of intended use of anticoagulants\n* Activated partial thromboplastin time (aPTT): \\\u003C=1.5 X ULN unless participant is receiving anticoagulant therapy if PT or aPTT is within therapeutic range of intended use of anticoagulants\n\nALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.\n\n1. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.\n2. Creatinine clearance (CrCl) should be calculated per institutional standard.\n\n   * Normal cardiac ejection fraction (\\>= 45% by echocardiogram) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram.\n   * Room air oxygen saturation of 90% or greater.\n   * Treatment-related toxicities from prior treatments must be resolved to \\\u003C= grade 2.\n   * Participants with CNS metastases, leptomeningeal disease or carcinomatous meningitis are eligible if they are asymptomatic, have completed their treatment for CNS disease and have recovered from the acute effects of radiation therapy or surgery prior to study entry. Participants must have radiographically stable CNS disease without associated edema at least three months prior to study entry. Additionally, participants have had to have discontinued corticosteroid treatment or non-prophylactic antiseizure medications for these metastases at least four weeks prior to study entry.\n   * Participants of child-bearing potential and participants who can father children must agree to use highly effective contraception or abstinence.\n   * Participants who are nursing or plan to nurse a child must agree to discontinue\u002Fpostpone nursing for the duration of study therapy and for 12 months after the administration of the cell product or for 4 months from the time no evidence of persistence\u002Fgene modified cells is documented in the participant s blood.\n   * Ability of participant to understand and the willingness to sign a written informed consent document.\n\n   EXCLUSION CRITERIA:\n\n   An individual who meets any of the following criteria will be excluded from participation in this study:\n   * Prior systemic therapy, an investigational therapy, radiation, and\u002For surgery within 14 days prior to leukapheresis and 21 days prior to lymphodepleting chemotherapy.\n   * Prior administration of anti-PD-1 or anti-PD-L1 antibodies or other agents that in the opinion of the PI can stimulate immune activity and interfere with an infusion of CAR-T cells within 8 weeks prior to treatment initiation.\n   * Participants with any form of primary immunodeficiency (e.g. severe combined immunodeficiency).\n   * Participants with active or history of autoimmune or immune mediated disease such as multiple sclerosis, lupus, inflammatory bowel disease, rheumatoid arthritis, or small vessel vasculitis. NOTE: Participants with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.\n   * History of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabine.\n   * Therapeutic doses of systemic corticosteroid therapy within 14 days prior to treatment initiation. Physiological doses of steroids (up to 5mg\u002Fday of prednisolone or equivalent) are allowed. Corticosteroid creams, ointments, and eye drops are allowed.\n   * Participants with lung fibrosis, inflammatory lung disease or evidence of pneumonitis on baseline imaging studies or medical history of these disorders.\n   * Participant has any other prior or concurrent malignancy with the following exceptions:\n\n     * Adequately treated basal cell or squamous cell carcinoma\n     * In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 12 months prior to initiation of study therapy.\n     * Treated non-melanoma skin cancer.\n     * Stage 0 or 1 melanoma completely resected at least 12 months prior to initiation of study therapy.\n     * Successfully treated organ-confined prostate cancer with no evidence of progressive disease based on PSA levels and are not on active therapy.\n     * A primary malignancy which has been completely resected and in complete remission for \\>= 5 years.\n   * Electrocardiogram showing a QTc interval \\> 450 msec in males and \\> 470 msec in females (\\> 80 msec for participants with bundle branch block). Either Fridericia s or Bazett s formula may be used to correct the QT interval.\n   * Participant has active infection with HIV, hepatitis B virus, HCV, or HTLV as defined below:\n\n     * Positive serology for HIV, HTLV-1, or HTLV-2.\n     * Active hepatitis B infection as demonstrated by test for hepatitis B surface antigen. Participants who are hepatitis B surface antigen negative but are hepatitis B core antibody positive must have undetectable hepatitis B DNA and receive prophylaxis against viral reactivation.\n     * Active hepatitis C infection as demonstrated by hepatitis C RNA test. Participants who are HCV antibody positive will be screened for HCV RNA by any reverse transcription PCR or branched DNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value.\n   * Participant is pregnant or intends to be pregnant during the required period of contraception for participants of childbearing potential.\n   * Participants who received live or attenuated vaccine or virus-based vaccine within 30 days before initiation of treatment initiation\n   * Participants with a history of seizure disorder unless due to now treated metastatic lesions.\n   * Ongoing uncontrolled intercurrent illness, including but not limited to ongoing or active infection, that would impact participant safety or limit compliance with study requirements.","120 Years",{"count":193,"type":21},100,[195],"PHASE1","Background:\n\nMesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person s own immune cells (T cells); the T cells are genetically modified to target and kill tumor cells with high levels of MSLN.\n\nObjective:\n\nTo test a new treatment (TNhYP218 CAR T cells) in people with solid tumors including mesothelioma.\n\nEligibility:\n\nPeople aged 18 and older with solid tumors including mesothelioma that returned or spread after standard treatment.\n\nDesign:\n\nParticipants will be screened. A small piece of tissue will be cut from a tumor (biopsy). The sample will be tested to see if it has enough MSLN.\n\nParticipants will undergo leukapheresis: Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein.\n\nParticipant s T cells will be modified in a lab to produce TNhYP218 CAR T cells.\n\nParticipants will enter the hospital. For 7 days, they will receive drugs to prepare their bodies for the study treatment.\n\nTNhYP218 CAR T cells will be administered into a vein. Participants will remain in the hospital for at least 7 more days.\n\nAfter discharge, participants will have follow-up visits for 5 years. These visits may include imaging scans, blood and heart tests, and a new biopsy.\n\nLong-term follow-up will continue another 10 years....",[28,198,26,27,35,34,199,200],"Neoplasms","Thymus Neoplasms","Colonic Neoplasms",[202,203,204,205,206,207,64,208,209,210],"Peritoneal Mesothelioma","Thymic Carcinoma","Colon Cancer","Gastric Cancer","Lung Cancer","Ovarian Cancer","mesothelin expressing solid tumors","CAR T cell therapy","Gene Therapy",{"date":139,"type":41},{"date":213,"type":41},"2025-07-08",{"date":215,"type":21},"2044-06-01",{"name":45,"class":46},{"id":218,"slug":4,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":59,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":47},"100641123","NCT07656571","Indocyanine Green-Guided Versus Standard Laparoscopic Distal Pancreatectomy for Pancreatic Body and Tail Lesions","Indocyanine Green Fluorescence-Guided Versus Standard Laparoscopic Distal Pancreatectomy: A Prospective Randomized Controlled Trial","ICG-LDP","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Body mass index (BMI) ≤ 40 kg\u002Fm².\n* Radiologically confirmed lesion(s) of the pancreatic body and\u002For tail requiring elective distal pancreatectomy, with or without splenectomy.\n* Lesion amenable to a laparoscopic approach as determined by the operating surgeon on preoperative CT or MRI imaging.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Adequate hepatic function: serum bilirubin ≤ 2 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.\n* Patients who have received neoadjuvant chemotherapy, chemoradiotherapy, or radiotherapy are eligible if resectability is confirmed on restaging imaging and at least 3 weeks have elapsed since the last treatment dose.\n* Ability to provide written informed consent and willingness to comply with study follow-up.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to indocyanine green (ICG), iodine, or iodinated contrast agents.\n* Uncorrected coagulopathy (international normalized ratio \\> 1.5 or platelet count \\\u003C 80 × 10⁹\u002FL).\n* Pregnancy or breastfeeding.\n* Prior major upper abdominal surgery precluding safe laparoscopic access (for example previous pancreatectomy or gastrectomy) as judged by the surgeon.\n* Presence of distant metastases or locally advanced disease requiring vascular resection at the time of surgery.\n* American Society of Anesthesiologists (ASA) physical status classification IV or V.\n* Severe hepatic impairment (Child-Pugh class C).\n* Inability or unwillingness to comply with scheduled follow-up visits and assessments.\n* Concurrent participation in another interventional clinical trial.",{"count":225,"type":21},72,[61],"Postoperative pancreatic fistula is the most important complication after laparoscopic distal pancreatectomy for tumors of the body and tail of the pancreas. It can cause infection, bleeding, longer hospital stay, and even death. New imaging technology using indocyanine green (ICG) dye and near-infrared fluorescence may help surgeons see blood flow to the pancreatic stump, spleen, and nearby vessels during surgery and make safer decisions about where to cut and which structures to preserve.\n\nThis study will compare two standard laparoscopic operations for pancreatic body and tail lesions: one with ICG fluorescence imaging at key steps of the procedure and one without ICG imaging. Adult patients who need elective laparoscopic distal pancreatectomy will be randomly assigned to one of the two groups. All other aspects of care before, during, and after surgery will be the same.\n\nThe main goal is to find out whether using ICG fluorescence can reduce the rate of clinically relevant postoperative pancreatic fistula (Grade B or C) within 90 days after surgery. Secondary goals include comparing blood loss, operating time, need to convert to open surgery, spleen preservation, complications, hospital stay, and oncologic outcomes such as margin status and lymph node yield.",[27,64],[230,231,232,233,234,235],"Laparoscopic distal pancreatectomy","Distal pancreatectomy","Pancreatic body and tail lesions","Pancreatic ductal adenocarcinoma","ICG fluorescence imaging","ICG-guided surgery","2026-06-15",{"date":178,"type":41},{"date":239,"type":41},"2026-06-09",{"date":241,"type":21},"2027-02-01",{"name":243,"class":121},"Alexandria University",{"id":245,"slug":4,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":59,"phases":251,"briefSummary":253,"conditions":254,"keywords":262,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100643560","NCT07631871","An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy","Inclusion Criteria:\n\n1. Male or female subjects aged ≥ 18 years old.\n2. Subjects with locally advanced, unresectable or metastatic solid tumors who have progressed after ≥1 prior systemic therapy for advanced\u002Fmetastatic disease, or have no available optimal alternative treatments. Qualified tumor types include but are not limited to endometrial carcinoma, urothelial carcinoma, pancreatic cancer, colorectal carcinoma (CRC), head and neck adenocarcinoma (salivary gland adenocarcinoma, lacrimal gland adenocarcinoma, adenocarcinoma of unknown primary of the neck), cervical cancer, ovarian cancer and adenocarcinoma of unknown primary. Biliary tract malignancy, lung cancer and breast cancer are excluded. For CRC patients: documented RAS status (wild-type or mutant) and wild-type BRAF; prior treatment regimen should contain fluoropyrimidine, oxaliplatin and irinotecan unless contraindicated; anti-VEGF therapy when clinically indicated; anti-PD-L1 therapy for MSI-H\u002FdMMR tumors if clinically indicated.\n3. ECOG Performance Status 0, 1 or 2.\n4. Confirmed HER2 positivity defined as IHC 3+, or IHC 2+ with positive FISH amplification (per GC criteria).\n5. Willing and capable of providing adequate tumor specimens for central pathological re-assessment of HER2 status at institutional pathology department. Patients previously treated with HER2-ADC must provide FFPE tumor samples collected after last HER2-ADC administration. Specimens with insufficient tumor cellularity and fine-needle aspiration samples are not acceptable for HER2 testing.\n6. At least one measurable lesion at baseline per RECIST 1.1 criteria.\n7. Adequate bone marrow and organ function confirmed within 14 days prior to enrollment: Hemoglobin ≥ 9 g\u002FdL; Platelet count ≥ 75,000\u002Fmm³; Absolute neutrophil count (ANC) ≥ 1000\u002Fmm³; Serum albumin ≥ 2.5 g\u002FdL; PT, aPTT and INR ≤ 1.5 × ULN; AST\u002FALT ≤ 3 × ULN; ≤5 × ULN for subjects with liver metastasis; Total bilirubin ≤1.5 × ULN (no liver metastasis); ≤3 × ULN (baseline Gilbert syndrome or liver metastasis); Creatinine clearance ≥30 mL\u002Fmin (calculated by Cockcroft-Gault formula)\n8. LVEF ≥50% evaluated via echocardiogram (ECHO) or MUGA scan within 28 days before enrollment.\n\nExclusion Criteria:\n\nSubjects with any of the following conditions are ineligible:\n\n1. Documented spinal cord compression, leptomeningeal disease or clinically active central nervous system (CNS) metastasis.\n2. Active primary immunodeficiency, confirmed HIV infection, active HBV or HCV infection.\n3. History of non-infectious interstitial lung disease (ILD)\u002Fnon-infectious pneumonia requiring steroid therapy, ongoing active ILD\u002Fnon-infectious pneumonia, or suspected ILD\u002Fnon-infectious pneumonia that cannot be ruled out by screening imaging.\n4. History of myocardial infarction, symptomatic congestive heart failure (CHF, NYHA Class II-IV), unstable angina, or any cardiovascular event (including stroke) within 6 months prior to enrollment.\n5. Pulmonary exclusion items: (a) Clinically significant underlying pulmonary disorders, including but not limited to pulmonary embolism within 3 months before screening, severe asthma, severe COPD, restrictive lung disease, recurrent pleural effusion; (b) Confirmed autoimmune, connective tissue or inflammatory diseases (rheumatoid arthritis, Sjögren's syndrome, sarcoidosis etc.), or suspected pulmonary involvement at screening; full disease details shall be recorded in eCRF for enrolled subjects; (c) Previous total pneumonectomy.\n6. Confirmed presence of HER2 gene mutation.",{"count":250,"type":21},10,[252],"PHASE2","The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg\u002Fkg per cycle.",[198,255,256,257,258,27,259,260,261,35],"Solid Tumors","HER2 Positive Solid Tumor","Endometrial Neoplasm","Urothelial Carcinoma (UC)","Colorectal Neoplasms","Head and Neck Neoplasms","Cervical Neoplasms",[256,263,264],"Zanidatamab","Basket Study","2026-06-02",{"date":267,"type":41},"2026-06-08",{"date":236,"type":21},{"date":270,"type":21},"2029-12-31",{"name":272,"class":121},"Haihua Yuan",{"id":274,"slug":4,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":59,"phases":280,"briefSummary":281,"conditions":282,"keywords":292,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":298,"leadSponsor":299,"locationsCount":4},"100643697","NCT07631884","Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","Inclusion Criteria:\n\n1. Male and female participants aged 18 years or older.\n2. Participants with locally advanced, unresectable or metastatic solid tumors who have progressed after at least one prior systemic therapy for advanced\u002Fmetastatic disease, or have no satisfactory alternative treatment options. Eligible tumor types include but are not limited to biliary tract cancer, endometrial cancer, urothelial carcinoma, pancreatic cancer, colorectal cancer, gastric cancer, non-small cell lung cancer, head and neck adenocarcinoma (salivary gland adenocarcinoma, lacrimal gland adenocarcinoma, adenocarcinoma of unknown primary in the neck), cervical cancer, ovarian cancer and adenocarcinoma of unknown primary. Breast cancer is excluded.\n3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n4. Confirmed HER2 expression defined as IHC 1+, 2+ or 3+ (per GC criteria).\n5. Willing and able to provide adequate tumor specimens for central pathological re-testing of HER2 status. For participants previously treated with anti-HER2 therapy, tumor specimens obtained after the last anti-HER2 treatment are optional.\n6. At least one measurable lesion at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n7. Adequate organ and bone marrow function within 14 days prior to enrollment, meeting the following criteria:\n\n   Hemoglobin ≥ 9 g\u002FdL; Platelet count ≥ 100,000\u002Fmm³; Absolute neutrophil count (ANC) ≥ 1500\u002Fmm³; Serum albumin ≥ 3.0 g\u002FdL; Prothrombin time (PT), activated partial thromboplastin time (aPTT) and International Normalized Ratio (INR) ≤ 1.5 × upper limit of normal (ULN); Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 × ULN; ≤ 5 × ULN for participants with liver metastases; Total bilirubin ≤ 1.5 × ULN for participants without liver metastases; ≤ 3 × ULN for participants with Gilbert's syndrome or liver metastases at baseline; Creatinine clearance ≥ 30 mL\u002Fmin (calculated by the Cockcroft-Gault formula)\n8. Left ventricular ejection fraction (LVEF) ≥ 50% assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days prior to enrollment.\n\nExclusion Criteria:\n\nParticipants meeting any of the following conditions are ineligible for this study:\n\n1. Presence of any severe and\u002For uncontrolled diseases:\n\n   * Poorly controlled blood pressure (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); poorly controlled diabetes (fasting blood glucose \\[FBG\\] \\> 10 mmol\u002FL).\n   * Grade ≥ 2 myocardial ischemia, myocardial infarction, arrhythmia (QTc interval ≥ 470 ms), or Grade ≥ 2 congestive heart failure (per New York Heart Association \\[NYHA\\] classification).\n   * Active or uncontrolled severe infections (Grade ≥ 2 per NCI CTCAE) requiring systemic antibacterial, antifungal or antiviral therapy, including pulmonary tuberculosis.\n   * History of active tuberculosis.\n   * Uncontrolled ascites, pericardial effusion or pleural effusion requiring repeated drainage.\n2. Active hepatitis: Liver function not meeting the inclusion criteria. Hepatitis B: HBV DNA ≥ 2000 IU\u002FmL or ≥ 10\\^4 copies\u002FmL.Hepatitis C: HCV RNA ≥ 2000 IU\u002FmL or ≥ 10\\^4 copies\u002FmL. Participants with viral load below the above thresholds after nucleoside antiviral therapy are eligible. Chronic hepatitis B virus carriers with HBV DNA \\\u003C 10\\^4 IU\u002FmL must receive concurrent antiviral treatment throughout the study for enrollment.\n3. History of immunodeficiency diseases, including HIV positivity or other acquired\u002Fcongenital immunodeficiency disorders.\n4. History of allogeneic solid organ transplantation or allogeneic hematopoietic stem cell transplantation.\n5. Confirmed meningeal metastasis, spinal cord metastasis or spinal cord compression.\n6. Within 6 months prior to the first study drug administration, presence of esophageal gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, acute gastrointestinal bleeding, extensive intestinal resection (partial colectomy or extensive small bowel resection complicated with chronic diarrhea), Crohn's disease, ulcerative colitis or long-standing chronic diarrhea.\n7. Unhealed or poorly healing wounds, or active ulcers.\n8. Toxicities from prior anti-tumor therapy have not resolved to Grade 0 or 1 per NCI CTCAE version 5.0.\n9. Received major surgery, incisional biopsy or significant traumatic injury within 28 days before study treatment initiation; or with long-standing unhealed wounds or fractures.\n10. History of severe hypersensitivity reactions to monoclonal antibodies; known allergy to the active ingredients or excipients of the study drug.",{"count":279,"type":21},15,[252],"The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.\n\nThe main question it aims to answer is: What is the objective response rate of Trastuzumab Rezetecan in adult patients with HER-2 expressed advanced solid tumors? Participants will receive intravenous infusion of Trastuzumab Rezetecan on Day 1 of each 21-day treatment cycle. The dosage is 4.8 mg\u002Fkg per cycle; participants with a body weight of 85 kg or above will receive a fixed dose of 408 mg every 3 weeks.",[255,283,284,285,286,287,288,29,289,258,27,259,290,291,260,261],"Neoplasms (Cancer \u002F Tumors)","Advanced Malignant Solid Neoplasm","Locally Advanced Malignant Solid Neoplasm","Unresectable Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","HER2 Expression","Endometrial Neoplasms","Gastric Neoplasms","Non-Small Cell Lung Carcinoma (NSCLC)",[293,294,295],"HER2 expression","Trastuzumab Rezetecan","Advanced Solid Tumor",{"date":267,"type":41},{"date":236,"type":21},{"date":78,"type":21},{"name":272,"class":121},{"id":301,"slug":4,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":309,"conditions":310,"keywords":313,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":47},"100639244","NCT07608055","Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss After Pancreatectomy in Non-Diabetic Patients","Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss Following Partial, Near-Total, and Total Pancreatectomy in Patients Without Diabetes at Baseline: A Monocentric Ambispective Observational Study","DCP-NDM","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* No diabetes mellitus at baseline\n* Undergoing partial, near-total, or total pancreatectomy at the study center\n* Availability of clinical and metabolic data according to study component\n* Written informed consent for the prospective component\n\nExclusion Criteria:\n\n* Diabetes mellitus at baseline\n* Age \\\u003C18 years\n* Missing key clinical data precluding eligibility assessment or primary outcome evaluation\n* Refusal or inability to provide informed consent for the prospective component, where applicable",{"count":308,"type":21},579,"This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.\n\nThe study will include adults without diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS.\n\nResearchers will study whether participants develop diabetes after surgery and whether this risk changes according to the type of pancreatic resection.\n\nInformation from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.",[311,312,27],"Pancreatectomy","Diabetes Mellitus Type 2",[311,314,315,316,317],"New-Onset Diabetes","Pancreatic Surgery","Beta-Cell Function","type 2 diabetes","2026-05-21",{"date":320,"type":41},"2026-05-27",{"date":322,"type":21},"2026-05",{"date":324,"type":21},"2041-05",{"name":120,"class":121},{"id":327,"slug":4,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":335,"conditions":336,"keywords":337,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":344,"leadSponsor":345,"locationsCount":4},"100637884","NCT07607912","Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancreatectomy in Patients With Preoperative Diabetes Mellitus","Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancreatectomy in Patients With Preoperative Diabetes Mellitus: A Monocentric Ambispective Observational Study","DCP-DM","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Diabetes mellitus at baseline\n* Undergoing partial, near-total, or total pancreatectomy at the study center for benign or malignant pancreatic disease\n* Availability of clinical and metabolic follow-up data according to study component\n* Written informed consent for the ambispective and prospective components, where applicable\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Absence of diabetes mellitus at baseline\n* Missing essential clinical data or incomplete follow-up precluding evaluation of study outcomes\n* Severe pre-existing non-oncologic clinical conditions with life expectancy \\\u003C6 months\n* Refusal, withdrawal, or inability to provide informed consent for the ambispective and prospective components, where applicable",{"count":334,"type":21},408,"This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.\n\nThe study will include adults with diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS.\n\nResearchers will study whether glycemic control worsens after surgery and whether this risk changes according to the type of pancreatic resection. The study will also examine changes in glucose metabolism, and cancer-related outcomes.\n\nInformation from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.",[312,311,27],[312,338,339,340,311],"Metabolism","Beta Cells Function","Glycemic Control",{"date":342,"type":41},"2026-05-26",{"date":322,"type":21},{"date":324,"type":21},{"name":120,"class":121},{"id":347,"slug":4,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":59,"phases":354,"briefSummary":355,"conditions":356,"keywords":365,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":378},"100545354","NCT06380816","A Phase I\u002FII Trial of UCB4594 in Participants With Advanced Cancer","A Cancer Research UK Phase I\u002FII Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies","Inclusion Criteria:\n\n1. Written (signed and dated) informed consent and capable of co-operating with investigational medicinal product (IMP) administration and follow-up\n2. Participant population: Histologically or cytologically proven advanced solid tumours (as specified below), refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the participant. Module A (dose escalation): Tumour types which have shown high levels of human HLA-G expression (as reported in the literature): head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, renal cell cancer (clear cell only), oesophago-gastric cancer (excluding gastrointestinal stromal tumour), cervical cancer, ovarian cancer, pancreatic cancer. N.B. Participants with small cell type cancers on histology\u002Fcytology are excluded. Pre-treatment biopsies are mandatory for all participants. Paired biopsies will be mandatory for participants from doses of 30 mg and higher. Participants must have disease amenable to biopsy (excluding bone metastases) as deemed safe by the Investigator\n3. Measurable disease, according to RECIST v1.1\n4. Life expectancy of at least 12 weeks\n5. Eastern Cooperative Oncology Group performance status of 0 or 1\n6. Haematological and biochemical indices within defined ranges. These measurements should be performed to confirm the patient's eligibility to participate in the trial\n7. Aged 18 years or over at the time consent is given. Participants aged 16-17 years may be eligible for recruitment to the backfill cohorts in dose escalation once adequate safety and toxicity data have been established in participants aged 18 years or over. All relevant data will be reviewed and a decision on the inclusion of participants aged 16-17 years will be made by the Trial Management Group\n\nExclusion Criteria:\n\n1. Radiotherapy (except palliative), endocrine therapy (unless for non-malignant disease), chemotherapy, targeted therapy or immunotherapy, or any other IMPs during the previous 4 weeks or 5 half-lives (whichever is shorter) before the first dose of IMP\n2. Ongoing toxicity of previous treatments \\>CTCAE Grade 1 (except alopecia of any grade, stable Grade 2 peripheral neuropathy or hormone-replacement therapy (HRT)-managed endocrine disorders)\n3. Patients with rapidly progressing \u002F symptomatically deteriorating brain\u002Fleptomeningeal metastases\u002Funtreated brain metastases are excluded. Patients with previously treated brain metastases are eligible if they haven't had a seizure or a clinically significant change in neurological status or required steroids in the last 2 weeks\n4. Pregnant or breastfeeding female patients (or planning to breastfeed)\n5. Women of childbearing potential. However, those not already pregnant or breastfeeding (or who discontinue breastfeeding) and meet the following are eligible:\n\n   5.1. Have a negative serum pregnancy test within 7 days before enrolment and either:\n\n   5.2.1. Agree to a form of highly effective contraception plus a barrier method, or\n\n   5.2.2. Agree to sexual abstinence\n\n   Effective from the negative pregnancy test, throughout the trial and for 10 months after the last dose of UCB4594\n6. Male patients with partners of childbearing potential. However, patients who meet the following are eligible:\n\n   6.1. Agree to a barrier method of contraception or sexual abstinence\n\n   6.2. Males with pregnant or breastfeeding partners must use barrier method contraception to prevent exposure of the foetus or neonate\n\n   6.3. Non-vasectomised males must also ensure any partner of childbearing potential uses highly effective contraception or agrees to sexual abstinence\n\n   Effective from the date of the first dose of UCB4594, throughout the trial and for 5 months after the last dose of UCB4594 N.B. Males must refrain from donating sperm for the same period\n7. Surgery from which the patient has not yet recovered\n8. High medical risk because of non-malignant systemic disease, including serious or uncontrolled infection (requiring intravenous antibiotics) or unexplained fever \\>38°C within 2 weeks prior to the first dose of UCB4594\n9. Known to be serologically positive for hepatitis B virus, hepatitis C virus or human immunodeficiency virus\n10. Active or suspected autoimmune disease, or any history of autoimmune condition that required systemic corticosteroids or immunosuppressive agents. Patients who have ever had a transplant are excluded. This does not apply to patients with: vitiligo, alopecia, or type I diabetes mellitus, psoriasis not requiring chronic systemic immunosuppressive treatment within the past 2 years, stable autoimmune-mediated hypothyroidism on HRT, and Raynaud's syndrome\n11. Are being treated with escalating or supraphysiologic doses of corticosteroids or immunosuppressive agents. Participants with immunotherapy-related hypophysitis adequately treated with physiologic doses of steroids are not excluded. Use of topical, ophthalmic, inhaled, intermittent steroid injections, and intranasal corticosteroids are permitted\n12. Hypersensitivity to the ingredients\u002Fexcipients (including polysorbate 80) in UCB4594\n13. History of significant toxicities from treatment of immune checkpoint inhibitors (CPIs) that necessitated permanent discontinuation (Patients who started on combination CPI \\[e.g., ipilimumab\u002Fnivolumab\\] and had toxicity requiring discontinuation of one CPI \\[e.g., continued with nivolumab single agent\\] are not excluded)\n14. History of Grade ≥3 infusion-related reaction to monoclonal antibodies or similar drugs\n15. Prior treatment with HLA-G, immunoglobulin-like transcript (ILT)2 or ILT4-targeting drug\n16. Live, attenuated vaccine within 28 days prior to the first dose of IMP\n17. Increased risk due to tumour flare (e.g., an initial increase in tumour size that may lead to obstruction of airways, etc)\n18. Significant active pulmonary disease or condition at screening, including:\n\n    18.1. Lymphangitis carcinomatosa\n\n    18.2. History of interstitial lung disease or pulmonary fibrosis\n\n    18.3. History of pulmonary inflammatory disease\n19. Evidence of bleeding diathesis\n20. Significant cardiovascular disease, defined as a history of: congestive heart failure requiring therapy or left ventricular ejection fraction \\\u003C40%, unstable angina pectoris or myocardial infarction within 6 months prior to entry, or current poorly controlled angina (symptoms weekly or more), clinically significant cardiac arrhythmia within 6 months prior to entry (asymptomatic atrial fibrillation or asymptomatic first-degree heart block permitted), or myocarditis. Presence of symptomatic or severe valvular heart disease. Baseline QT interval corrected by Fridericia \\>450 msec for males and \\>470 msec for females on triplicate electrocardiogram is ineligible\n21. Participant in or plans to join another interventional trial\n22. Other current malignancies. Cancer survivors who have undergone potentially curative therapy for prior malignancy with no evidence of disease for 3+ years are eligible\n23. Any other condition that, in the Investigator's opinion, means the trial is not in the patient's best interest",{"count":353,"type":21},167,[195,252],"This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells.\n\nThe four main aims of the clinical trial are to find out:\n\n1. The best dose of UCB4594 that can be given safely to participants in the trial.\n2. What the side effects of UCB4594 are and how they can be managed.\n3. What happens to UCB4594 inside the body and how it affects cancer cells.\n4. Whether UCB4594 can cause cancer to shrink.",[357,358,359,259,360,361,362,363,364,35,27],"Advanced Solid Tumours","Squamous Cell Carcinoma of Head and Neck","Carcinoma, Non-Small-Cell Lung","Triple Negative Breast Neoplasms","Carcinoma, Renal Cell (Clear Cell Only)","Esophageal Neoplasms","Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)","Uterine Cervical Neoplasms",[366,367,368],"HLA-G","Monoclonal Antibody","Cancer","2026-05-05",{"date":371,"type":41},"2026-05-08",{"date":373,"type":41},"2024-07-09",{"date":375,"type":21},"2029-11",{"name":377,"class":121},"Cancer Research UK",4,{"id":380,"slug":4,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":47},"100509558","NCT05914987","Determining Individualized Cancer Therapy in Pancreatic Cancer","Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)","PREDICT-PANC","Inclusion Criteria:\n\n* Age ≥18 years.\n* Pathologically confirmed pancreatic cancer.\n* Ability to understand a written informed consent document and the willingness to sign it\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Primary cancer diagnosis other than pancreatic cancer.",{"count":20,"type":21},"This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.",[27],[390,391,392,368,393],"Mutation","Genomics","Targeted Therapy","Pancreas","2026-04-29",{"date":369,"type":41},{"date":397,"type":41},"2023-12-04",{"date":399,"type":21},"2033-08-01",{"name":401,"class":121},"Medical College of Wisconsin",{"id":403,"slug":4,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":59,"phases":410,"briefSummary":411,"conditions":412,"keywords":415,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":47},"100634619","NCT07542041","Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens","Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)","ANoPs","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to understand and willingness to sign a written informed consent form\n* Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study",{"count":131,"type":21},[61],"The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy.\n\nThe main questions this study aims to answer are:\n\n* Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer?\n* How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment?\n\nThis is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance.\n\nParticipants will:\n\n* Undergo a standard-of-care pancreatic biopsy or surgical procedure\n* Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device\n* Continue to receive standard treatment and care, which is not influenced by the study\n* Have clinical data, imaging results, and treatment outcomes collected\n* Be followed every 3 months for up to 2 years\n\nThe study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.",[64,27,413,414],"Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Lesions Located at the Body or the Tail",[416,417,418,419,420,64],"Atomic Force Microscopy","Neoadjuvant Therapy","Nanomechanical Profiling","NEO-Match","Pancreatic Ductal Adenocarcinoma","2026-04-14",{"date":423,"type":41},"2026-04-21",{"date":425,"type":21},"2026-04",{"date":427,"type":21},"2030-05",{"name":429,"class":81},"ARTIDIS AG",{"id":431,"slug":4,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":55,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":436,"conditions":437,"keywords":440,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":47},"100393729","NCT04406831","The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer","Inclusion Criteria:\n\n* Have biopsy proven adenocarcinoma of the pancreas\n* Have initially inoperable disease, classified as either locally advanced or metastatic disease\n\n  * Recurrent disease after a Whipple procedure is allowed\n  * Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection\n* Have radiographically measurable disease\n* Have an ECOG performance status of 2 or less\n* Be willing to contribute the required information and specimens\n* Provide written signed consent to participate\n\nExclusion Criteria:\n\n* Having received prior anti-cancer treatments for metastatic pancreatic cancer\n* Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable\u002Fcontrolled prostate cancer\n* Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \\>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \\> 5 years is allowable",{"count":131,"type":21},"Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood\u002Fserum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.",[438,439,420,27],"Pancreatic Cancer Stage III","Pancreatic Cancer Stage IV",[393,368,441],"Biomarker","2026-04-06",{"date":444,"type":41},"2026-04-13",{"date":446,"type":41},"2015-04",{"date":448,"type":21},"2030-04",{"name":450,"class":121},"Nuvance Health",{"id":452,"slug":4,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":55,"sex":16,"minAge":458,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":461,"conditions":462,"keywords":464,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":184},"100357699","NCT03937453","A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus","A PAncreatic Cancer Screening Study in Individuals With New-Onset or DeteriOrating Diabetes MEllitus (PANDOME Study)","PANDOME","Inclusion Criteria:\n\n* Age of at least 50 years.\n* DM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c ≥ 6.5% OR\n* DM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR\n* Transition from pre-Diabetes to Diabetes Mellitus within the past 12 months characterized by a change in the HbA1c of ≥ 0.5% OR\n* DM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%. OR\n* Deteriorating Diabetes: DM with \\>2% spike in HbA1c within past 6 months confirmed with repeat testing and NOT associated with weight gain and diabetes medication non-compliance\n* ECOG Performance Status of 0-1.\n* No known contraindications to MRI examination or gadolinium contrast.\n* Willing to undergo MRI and screening for metal implants or metal injury.\n* Ability to provide informed consent.\n* Willing to return to study site for all study assessments.\n\nExclusion Criteria:\n\n* Prior history of pancreatic cancer.\n* Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.\n* Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).\n* Hereditary pancreatitis.\n* Use of high dose glucocorticoid steroids (at least 20 mg daily of prednisone) within 3 months of diabetes diagnosis or elevation of HbA1c. Lower doses of steroid use as a cause of glucocorticoid-induced diabetes will be made on a case-by-case basis.\n* Contraindication to MRI examination or gadolinium contrast.\n* Pregnant or nursing women.\n* Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.","50 Years",{"count":460,"type":21},800,"The main goal of this study is to explore the relationship between new-onset diabetes mellitus\u002Fdeteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI\u002FMRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pancreatic cancer.",[64,27,463],"Diabetes Mellitus",[393,368,463,465,466,467],"MRI","Early Detection","Screening",{"date":444,"type":41},{"date":470,"type":41},"2018-01-19",{"date":472,"type":21},"2028-01-19",{"name":450,"class":121},{"id":475,"slug":4,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":16,"minAge":458,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":47},"100304968","NCT03250078","A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals","Registration-Inclusion Criteria for FAMILIAL PANCREATIC CANCER (FPC) and those with a BRCA1, BRCA2, LYNCH SYNDROME, ATM, PALB2, CDKN2A, or related gene mutation (one of the following is required for questions 1-3)\n\n1. For FPC: The individual has at least 2 first-degree relatives (FDR) with PC.\n2. For FPC: The individual has at least 3 first-, second-, or third-degree relatives with PC with at least 1 PC in a FDR.\n3. The individual is a known mutation carrier of BRCA1, BRCA2, MLH1, MSH2, MSH6, or PMS2, ATM, PALB2, CDKN2A, or similar high-risk gene mutation and has at least 1 first- or second-degree relative with PC.\n4. The individual is at least 50 years old or 10 years younger than the youngest relative with PC.\n5. ECOG Performance Status of 0-1.\n6. No known contraindications to MRI examination or gadolinium contrast.\n7. Willing to undergo MRI and screening for metal implants or metal injury.\n8. Estimated GFR \\>29 mL\u002Fmin\n9. Ability to provide informed consent.\n10. Willing to return to study site for all study assessments.\n\nRegistration-Exclusion Criteria:\n\n1. Prior history of pancreatic cancer.\n2. Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.\n3. Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).\n4. Hereditary pancreatitis.\n5. eGFR \\\u003C 30 mL\u002Fmin\n6. Contraindication to MRI examination or gadolinium contrast.\n7. Pregnant or nursing women.\n8. Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.","90 Years",{"count":131,"type":21},"The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI\u002FMRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for Pancreatic Cancer.",[27],[393,368,465,484,466,485,486,487,488,489],"BRCA","Genetics","ATM","PALB2","Lynch","CDKN2A",{"date":444,"type":41},{"date":492,"type":4},"2016-11",{"date":494,"type":21},"2030-11",{"name":450,"class":121},{"id":497,"slug":4,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":59,"phases":503,"briefSummary":504,"conditions":505,"keywords":508,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":47},"100589344","NCT06953193","Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia","Inclusion Criteria:\n\n* Signed written informed consent.\n* Patients scheduled for elective pancreatoduodenectomy at National Institute of Medical Sciences and Nutrition Salvador Zubirán.\n* No contraindications for neuroaxial anesthesia (epidural catheter placement), including:\n\n  * Generalized or localized infection at the puncture site.\n  * Thrombocytopenia.\n  * Coagulation disorders.\n  * Intracranial hypertension.\n  * Patient refusal.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Pregnancy.\n* Inability to randomize the case due to specific circumstances (such as contraindications to epidural use), resulting in non-eligibility based on participation criteria.",{"count":502,"type":21},206,[61],"This randomized clinical trial compares the hemodynamic effects of general anesthesia versus combined general anesthesia (thoracic epidural) in patients undergoing pancreatoduodenectomy. The primary aim is to assess the incidence of intraoperative hypotension and related adverse events. Secondary outcomes includes vasopressor requirements, transfusion needs, postoperative complications, intensive care unit admission, hospital length of stay, and mortality.",[27,506,507],"Hypotension","Pancreatoduodenectomy",[315,509,510,511,512,513],"General Anesthesia","Hemodynamic Changes","Vasopressors","Postoperative Complications","Combined Anesthesia","2026-03-27",{"date":516,"type":41},"2026-04-01",{"date":518,"type":41},"2025-04-07",{"date":520,"type":21},"2030-04-30",{"name":522,"class":121},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":524,"slug":4,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":59,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":47},"100631729","NCT07504471","Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases","A Prospective, Single-Center, Phase II Clinical Study of Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen (Liposomal Irinotecan, Oxaliplatin, and S-1) Hepatic Arterial Infusion Chemotherapy (HAIC) and Intra-Arterial Programmed Death-1 (PD-1) Inhibitors for Liver Metastases From Pancreatic Cancer","Inclusion Criteria:\n\n* Aged 18 years and above, with no gender restrictions;\n* Pathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium), with metastasis to the liver;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;\n* Adequate organ function, meeting the following criteria:\n\n  a. Hematological tests:\n  1. Neutrophils ≥ 1.5 × 10⁹ \u002FL;\n  2. White blood cells ≥ 3.0 × 10⁹ \u002FL;\n  3. Platelets ≥ 85 × 10⁹ \u002FL;\n  4. Hemoglobin ≥ 70 g\u002FL; b. Biochemical tests:\n\n  \u003C!-- -->\n\n  1. Total bilirubin ≤ 2× upper limit of normal (ULN) (for subjects with biliary obstruction, after biliary drainage ≤ 2.5 × ULN);\n  2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in metastatic subjects ≤ 5 × ULN;\n  3. Albumin level ≥ 28 g\u002FL;\n  4. Creatinine clearance rate ≥ 60 ml\u002Fmin; c. Cardiac function tests:\n\n  \u003C!-- -->\n\n  1. Normal electrocardiogram (ECG) or ECG abnormalities deemed clinically insignificant by the investigator;\n  2. Left ventricular ejection fraction (LVEF) ≥ lower limit of normal;\n* At least 3 weeks post-surgery, radiotherapy, chemotherapy, or other anti-tumor treatments, with general physical condition or related adverse reactions having recovered (toxicity ≤ grade 1) or stabilized;\n* Willing to participate and sign the informed consent form;\n* Good compliance and agreement to cooperate with survival follow-up.\n\nExclusion Criteria:\n\n* Subjects with ascites requiring clinical intervention (including moderate to large amounts of ascites; subjects with ascites need to be stable for more than 4 weeks after drainage);\n* Clinically severe gastrointestinal diseases (including bleeding, infectious inflammation, perforation, obstruction, or diarrhea greater than grade 1);\n* NRS pain score ≥ 4 after standardized treatment with analgesics;\n* Second primary malignancy within 5 years (except cured carcinoma in situ, basal cell, or squamous cell skin cancer; subjects with other previous tumors can be enrolled if there has been no recurrence within 5 years);\n* Uncontrolled cardiovascular or cerebrovascular diseases with clinical symptoms, including but not limited to: ① NYHA class III or higher heart failure; ② unstable angina; ③ myocardial infarction or stroke within 6 months; ④ supraventricular or ventricular arrhythmias requiring treatment or intervention; ⑤ uncontrolled hypertension (systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 90 mmHg despite optimal treatment);\n* Known active hepatitis B subjects (HBsAg positive and HBV DNA ≥ 10³ copies or ≥ 1000 U\u002Fml);\n* Active infection or unexplained fever \\> 38.5°C during the screening period or on the day of administration (subjects with fever caused by tumors can be enrolled as judged by the investigator), which, in the investigator\\'s judgment, would affect the subject\\'s participation in this trial or interfere with the evaluation of efficacy;\n* Pregnant or breastfeeding women;\n* Women of childbearing potential with a positive blood (urine) pregnancy test during the screening period (both male and female subjects should use reliable contraception during the trial and for 3 months after the last dose to prevent pregnancy);\n* Subjects with other medical or social issues that, in the investigator\\'s judgment, might affect their ability to sign informed consent, participation in the trial, or interpretation of the trial results;\n* Patients with an estimated survival time of ≤ 3 months are not included in this study.",{"count":530,"type":21},50,[252],"This Phase II clinical study evaluates the safety and efficacy of a combination therapy for patients with pancreatic cancer that has spread to the liver. Because liver metastases are a major factor in the progression of pancreatic cancer, this research utilizes Hepatic Arterial Infusion Chemotherapy (HAIC) to deliver high-concentration treatment directly into the tumor's blood supply. The multi-step strategy involves first infusing Sodium Bicarbonate to neutralize the acidic tumor microenvironment , followed by the NASOX chemotherapy regimen (Oxaliplatin and Liposomal Irinotecan) and an intra-arterial PD-1 inhibitor to boost immune response. Patients also receive oral S-1 to maintain treatment effect. The primary goal is to determine if this integrated approach can improve Overall Survival for patients compared to historical standard treatments.",[27,534],"Hepatic Metastasis of Pancreatic Cancer","2026-03-26",{"date":537,"type":41},"2026-03-31",{"date":539,"type":21},"2026-03-23",{"date":541,"type":21},"2027-12-31",{"name":543,"class":121},"Ruijin Hospital",{"id":545,"slug":4,"hasResults":11,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":551,"enrollmentInfo":552,"targetDuration":553,"studyType":22,"phases":4,"briefSummary":554,"conditions":555,"keywords":557,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":564,"leadSponsor":566,"locationsCount":47},"100630319","NCT07486128","Microplastics in Pancreas: Oncologic and Metabolic Impact","Unveiling Microplastics in Human Pancreatic Tissue - Oncological and Metabolical Implications","PAN-Plastic","Inclusion Criteria:\n\nage between 18 and 80 years patients scheduled for elective pancreatic resection for benign or malignant pancreatic disease ability to understand and provide written informed consent no contraindications to general anesthesia\n\nExclusion Criteria:\n\nage \\\u003C18 or \\>80 years severe hepatic insufficiency (Child-Pugh class C) pregnancy or breastfeeding inability to understand the study procedures or provide informed consent","80 Years",{"count":250,"type":21},"12 Months","Microplastics and nanoplastics (MNPs) are emerging environmental contaminants that have been detected in several human tissues, raising concerns about their potential impact on human health. However, their presence in the human pancreas has not yet been investigated.\n\nThe aim of this prospective, single-center study is to detect and characterize microplastics in human pancreatic tissue obtained from patients undergoing pancreatic resection for benign or malignant diseases. Microplastics will also be analyzed in peripancreatic adipose tissue and peripheral blood. Advanced imaging techniques, including fluorescence microscopy, confocal microscopy, and Raman spectroscopy, will be used for identification and characterization.\n\nSecondary objectives include the evaluation of potential associations between microplastic burden and pancreatic metabolic function, assessed through clinical evaluation and metabolic testing. This proof-of-concept study aims to provide the first evidence of microplastic presence in the human pancreas and explore their potential role in metabolic dysfunction and carcinogenesis.",[556,27],"Pancreatic Diseases",[558,556,27,106,559,560],"Microplastics","Raman Spectroscopy","Pancreatic Tissue","2026-03-24",{"date":514,"type":41},{"date":516,"type":21},{"date":565,"type":21},"2027-04-01",{"name":120,"class":121},{"id":568,"slug":4,"hasResults":11,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":55,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":59,"phases":574,"briefSummary":575,"conditions":576,"keywords":577,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":47},"100302531","NCT03218345","EUS-guided RFA for Pancreatic Neoplasms","Multi-center Prospective Study on EUS-guided Radiofrequency Ablation for Solid Pancreatic Neoplasms","Inclusion Criteria:\n\n* Age 18 years-old or above\n* Suffering from pancreatic neuroendocrine tumor or pancreatic ductal carcinoma (\\\u003C5cm in largest diameter) that was confirmed by fine needle aspiration cytology\n* Unsuitable for surgery, due to one (or more) of the following items:\n\n  * ASA score \\> II\\*\n  * An alternative advanced malignancy\n  * Unsuitable for surgery upon expert's opinion for any other reason\n* Healthy individuals who are not keen for surgical resection\n* Eligible for endoscopic intervention\n* Written informed consent\n\nExclusion Criteria:\n\n* Coagulopathy (international normalized ratio \\>1.3, partial thromboplastin time greater than twice that of control), platelet count \\\u003C50,000x103\u002FuL\n* Pregnancy\n* Patients with a poor mental condition or mental retardation, unable to understand the nature and possible consequences of the study\n* Patients unwilling to undergo follow-up assessments\n* Patients with liver cirrhosis, portal hypertension and\u002For gastric varices.",{"count":155,"type":21},[61],"Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms. The procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic neoplasms.\n\nThe aim of the current study is to perform a multi-center prospective study on EUS-guided radiofrequency ablation (RFA) of solid pancreatic neoplasms. The hypothesis is that EUS-guided RFA is safe, feasible and effective for treating solid pancreatic neoplasms.",[27],[578,579,580],"EUS-guided RFA","pancreatic ca","interventional EUS","2026-03-19",{"date":583,"type":41},"2026-03-20",{"date":585,"type":41},"2016-08",{"date":587,"type":21},"2027-05",{"name":589,"class":121},"Chinese University of Hong Kong",{"id":591,"slug":4,"hasResults":11,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":59,"phases":598,"briefSummary":599,"conditions":600,"keywords":602,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":47},"100629649","NCT07477418","PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP): A Phase Ib\u002FII Open-Label Trial","PRISM-TAMP","Inclusion Criteria:\n\n* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).\n* Borderline resectable disease as defined by the ABC classification criteria, incorporating one or more of the following:\n\n  * Anatomy (A): Vascular involvement consistent with borderline resectable or resectable locally advanced-PDAC (e.g., abutment of the superior mesenteric vein or artery, portal vein, or celiac axis) as determined by cross-sectional imaging\n  * Biology (B): Concern for extra-pancreatic metastasis or known N1 disease or suspicious but nonconfirmatory liver\u002Flung lesion(s). CA19-9\\>500 after normalized bilirubin\n  * Condition (C): Functional status and comorbidity profile adequate for curative-intent surgery, as assessed by the multidisciplinary team, specifically WHO PS \\>\u002F=1.\n* No prior treatment for PDAC (e.g., chemotherapy, radiation, or surgery).\n* Age ≥ 18 years.\n* ECOG performance status of 0 or 1.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Locally Advanced PDAC or metastatic PDAC\n* Histology other than adenocarcinoma\n* Non-accessible arterial anatomy\n* Gemcitabine hypersensitivity or contraindication to mFOLFIRINOX therapy based on provider assessment",{"count":250,"type":21},[195,252],"Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival outcomes, even when treated with modern chemotherapy and radiation. Patients with borderline resectable PDAC often receive neoadjuvant systemic therapy to improve the likelihood of successful surgical removal of the tumor, but rates of incomplete tumor regression and positive surgical margins remain high.\n\nThis Phase Ib\u002FII, single-arm study evaluates the safety and feasibility of adding trans-arterial microperfusion (TAMP) delivery of gemcitabine to standard neoadjuvant therapy for patients with borderline resectable PDAC. In this study, patients receive standard systemic chemotherapy with modified FOLFIRINOX followed by stereotactic body radiation therapy (SBRT). After completion of chemoradiation, gemcitabine is delivered directly to the tumor through the arterial blood supply using the RenovoCath® catheter system. Gemcitabine is an FDA-approved chemotherapy drug for pancreatic cancer, and the study is evaluating a novel method of delivering the drug rather than a new medication.\n\nThe primary objective of the study is to assess the safety and tolerability of neoadjuvant TAMP-delivered gemcitabine in this treatment setting. Secondary objectives include evaluation of surgical margin status and pathologic tumor regression following surgical resection. Exploratory analyses will examine relapse-free survival. Results from this study will help determine whether this locoregional chemotherapy approach can be safely integrated into neoadjuvant treatment strategies for patients with borderline resectable PDAC.",[413,601,27],"Borderline Resectable Pancreatic Cancer",[417,603,604],"Gemcitabine","Intra-arterial Chemotherapy","2026-03-12",{"date":607,"type":41},"2026-03-17",{"date":609,"type":21},"2026-12",{"date":611,"type":21},"2031-12",{"name":613,"class":121},"University of Vermont",{"id":615,"slug":4,"hasResults":11,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":621,"targetDuration":17,"studyType":22,"phases":4,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":665},"100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":622,"type":21},8000,"The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[168,625,626,627,628,629,630,631,632,633,634,635,636,637,638,206,639,640,641,642,643,644,645,646,64,647,27,648,260,649,650,198,651,652,163,653,654,655],"Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Tumor","Lung Neoplasm","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Tumor","Head and Neck Cancer","Head and Neck Tumor","Tumor","Bladder Cancer","Bladder Neoplasm","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":658,"type":41},"2026-03-05",{"date":660,"type":41},"2019-02-01",{"date":662,"type":21},"2030-08-01",{"name":664,"class":121},"UMC Utrecht",18,{"id":667,"slug":4,"hasResults":11,"nctId":668,"briefTitle":669,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":671,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":673,"conditions":674,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":47},"100398871","NCT04473794","Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts","Inclusion Criteria:\n\n* Adult patients age 18 years and older\n* Referred for assessment of a pancreatic cyst.\n\nExclusion Criteria:\n\n* Medically ill patients with American Society of Anesthesiologists class 4 or greater.\n* Inability to provide informed consent.\n* Pregnancy or lactation.",{"count":672,"type":21},5000,"The aims of this study are to determine the natural history of pancreatic cysts and to propose and prospectively validate a diagnostic approach and model for prediction of mucinous versus non-mucinous, and malignant versus non-malignant, pancreatic cysts using a combination of clinical, radiologic, and biomarker characteristics.",[27,675],"Pancreas Cancer","2026-02-26",{"date":678,"type":41},"2026-03-02",{"date":680,"type":41},"2022-07-20",{"date":682,"type":21},"2036-08-01",{"name":684,"class":121},"Johns Hopkins University",{"id":686,"slug":4,"hasResults":11,"nctId":687,"briefTitle":688,"officialTitle":689,"acronym":4,"eligibilityCriteria":690,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":4,"enrollmentInfo":691,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":693,"conditions":694,"keywords":698,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":710,"completionDateStruct":712,"leadSponsor":714,"locationsCount":4},"100563412","NCT06615830","Predictive Value of Transcriptome-based OncoTreat\u002FOncotarget and Organoid Testing in Metastatic Pancreatic Cancer.","HIPANC-002 - Observational Performance Study of Transcriptome-Based OncoTreat\u002FOncoTarget Testing With Patient-Derived Organoids in Metastatic Pancreatic Cancer","Inclusion criteria:\n\n* Informed Consent as documented by signature\n* Patients older than 18 years\n* Patients with metastatic pancreatic ductal adenocarcinoma\n* At least one lesion amenable for surgical excisional biopsy\n* ECOG Performance status 0-2\n* Radiologically measurable disease\n* Life expectancy \\> 3 months\n* Absolute leucocyte count \\>1.5 G\u002Fl, platelets \\>100 G\u002Fl\n* Serum creatinine \\\u003C1.5 times of the upper limit of normal or Clearance \\>50ml\u002Fmin (according to the CKD-EPI formula)\n\nExclusion criteria:\n\n* Known allergies or intolerance to one or more compounds present in one of the first line or second line regimens\n* Concomitant need for full anticoagulation that cannot be interrupted or bridged prior to tissue biopsy\n* ECOG PS \\>2\n* Heart failure (NYHA class III-IV)\n* Severe or uncontrolled concurrent illness\n* Active viral infection from HIV, HBV or HCV, even if under antiretroviral treatment\n* Myocardial infarction within the previous 6 months\n* Patients who are pregnant or breastfeeding",{"count":692,"type":21},185,"Pancreatic cancer is burdened by a survival of barely 10% at 5 years. About 80% of new cases do not qualify for surgery due to either locally-advanced or metastatic disease. In patients with good performance status (PS), palliative first-line treatments mainly consist of combination regimens, such as FOLFIRINOX, modified FOLFIRINOX or Gemcitabine-Abraxane. For subjects with a poor PS, instead, guidelines recommend single-agent infusions (e.g. Gemcitabine, Capecitabine or 5-FU alone). Nevertheless, upon disease progression therapeutic options are still scarce and with limited sustained efficacy.\n\nOverall survival in metastatic pancreatic cancer ranges between 9.1 and 13.5 months, while progression-free survival under either FOLFIRINOX or Gemcitabine-Abraxane spans between 5.5 and 6.4 months. This timespan reduces even further when standard second-line regimens must be initiated upon disease progression.\n\nNowadays, genomic and transcriptomic analysis are crucial tools in cancer research that enable the identification of genetic mutations and alterations that drive the development and progression of cancer. By studying the changes in the DNA and RNA sequences of cancer cells, researchers can gain insights into the underlying molecular mechanisms of cancer and identify potential therapeutic targets. Genomic analysis can identify specific mutations or alterations that are present in cancer cells, while transcriptomic analysis can reveal changes in gene expression that may be linked to disease progression or response to treatment. These analyses are an essential component for the development of precision medicine approaches, which aim to tailor cancer treatment to the individual genetic profile of each patient.\n\nPDOs can replicate in vitro the biological, genetic and molecular aspects of the primary tumour. Some of their advantages include their rapid growth compared to xenografts, the possibility to perform high-throughput drug screening, and their direct application to precision oncology by predicting best therapies. In this study they will be used as an in vitro comparator of the molecular tests to the clinical course of the patient.\n\nOverall, combining genomic and transcriptomic analysis with PDO technology in cancer research might lead to exponential capacity to provide oncologic patients with extremely tailored and effective cancer treatments in the future.\n\nFor HIPANC-002 these tests are being evaluated as non-interventional investigational IVD's. Test results are not to be used for protocol mandated therapy decisions.",[695,27,696,697],"Pancreas Neoplasms","Pancreatic Cancer Metastatic","Pancreatic Adenocarcinoma Metastatic",[699,700,701,702,703,704,705,706],"Pancreatic cancer","Pancreatic adenocarcinoma","Metastatic pancreatic adenocarcinoma","Organoid","Organoid-driven chemotherapy","Darwin Oncotreat","Darwin Oncotarget","Personalized chemotherapy","2026-02-07",{"date":709,"type":41},"2026-02-11",{"date":711,"type":21},"2026-06-01",{"date":713,"type":21},"2031-01",{"name":715,"class":121},"Prof. Dr. med. Dres. h.c. Jan Schmidt, MME",""]